News
NVS
108.70
-1.30%
-1.43
Trump to sign executive order aimed at lowering drug prices
TipRanks · 2h ago
Pharma Worries Shift to Prices From Trade. Trump's Next Plan Could Sink Stocks.
Barron‘s · 2d ago
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study
Benzinga · 2d ago
BUZZ-Verastem climbs on FDA approval of ovarian cancer therapy
Reuters · 3d ago
Novartis AG (NOVN) Gets a Sell from Barclays
TipRanks · 3d ago
Sarepta: ELEVIDYS DMD Treatment Setback Brings Downgrade To Hold Rating
Seeking Alpha · 4d ago
Pharma imports to U.S. surged in March ahead of tariffs, Reuters says
TipRanks · 4d ago
Fidelity Overseas Fund Q1 2025 Review
Seeking Alpha · 4d ago
Novartis price target raised to CHF 89 from CHF 86 at Berenberg
TipRanks · 5d ago
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight
Benzinga · 5d ago
NVS Quantitative Stock Analysis
NASDAQ · 5d ago
FDA announces expanded use of unannounced inspections at foreign facilities
TipRanks · 5d ago
Vanguard FTSE Developed Markets ETF: A Good Hedge Against the U.S. Market?
Barchart · 5d ago
Analysts’ Top Healthcare Picks: Roche Holding AG (RHHVF), Novartis (NVS)
TipRanks · 5d ago
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion
Benzinga · 6d ago
Trump to sign order streamlining U.S. drug manufacturing regulations, WaPo says
TipRanks · 6d ago
Fidelity International Discovery Fund Q1 2025 Commentary
Seeking Alpha · 6d ago
Why Novartis (NVS) is a Great Dividend Stock Right Now
NASDAQ · 6d ago
BioNTech names Ramon Zapata as CFO, succeeding Jens Holstein
TipRanks · 6d ago
Weekly Report: what happened at NVS last week (0428-0502)?
Weekly Report · 6d ago
More
Webull provides a variety of real-time NVS stock news. You can receive the latest news about Novartis through multiple platforms. This information may help you make smarter investment decisions.
About NVS
More
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Recently
Symbol
Price
%Change